Neuland Laboratories
16,049.00
+495.00(+3.18%)
Market Cap₹20,590.69 Cr
PE Ratio151.49
IndustryHealthcare
Company Performance:
1D+3.18%
1M+23.65%
6M+46.46%
1Y+26.54%
5Y+1,497.15%
View Company Insightsright
More news about Neuland Laboratories
23Jul 25
Neuland Laboratories Unveils Detailed Commission Structure for Executive Director's Reappointment
Neuland Laboratories has released an addendum to its 41st AGM notice, detailing the commission structure for Mr. Davuluri Saharsh Rao's reappointment. The performance-based structure caps the commission at 2% of net profits or INR 10 crores, whichever is lower. It employs a balanced scorecard approach with 60% weightage on financial parameters and 40% on non-financial metrics. A minimum 70% achievement against set goals is required for eligibility. The Board will determine the commission based on the Nomination and Remuneration Committee's recommendations.
14Jul 25
Neuland Laboratories Shares Surge 12% on Final Dividend Announcement
Neuland Laboratories' stock price increased by 12% to Rs 13,750.00 following the announcement of a final dividend of Rs 12.00 per share (120% of face value) for the fiscal year 2025. The record date for dividend eligibility is set for July 18, 2025. The stock is trading above all eight Simple Moving Averages, indicating strong upward momentum.
17Jun 25
SEBI Issues Administrative Warning to Neuland Laboratories Over Insider Trading Violation
Neuland Laboratories has been issued an administrative warning by SEBI for violating insider trading regulations. The violation pertains to non-compliance with pre-clearance requirements by a designated person within the company. Neuland Laboratories states that the issue is individual-specific and has no material impact on its financials or operations.
17May 25
Neuland Laboratories Stock Plunges 7% as Q4 Profit Nosedives 59%
Neuland Laboratories experienced a significant stock price decline of nearly 7% following disappointing Q4 FY2025 results. The company reported a 59% drop in profit after tax, with revenue decreasing by 13.99% year-over-year. Net profit fell by 58.88%, and EPS dropped from Rs 52.66 to Rs 21.67. The decline is attributed to increased operating costs and reduced sales volumes. Despite providing strong future guidance, investor caution persists, as reflected in the continued downward pressure on the stock price.
16May 25
Neuland Laboratories: Shares Drop 11% Despite FY26 Growth Assurance
Neuland Laboratories reported a 59% decrease in Q4 consolidated net profit to ₹278.10 crore, with revenue falling 15% to ₹328.00 crore. The company's shares dropped 11% following the weak results. Despite the downturn, Neuland expects growth to resume in FY26. Goldman Sachs maintains a 'Buy' rating with a ₹14,775.00 target price. The company announced a final dividend of ₹12.00 per equity share.
15May 25
Neuland Laboratories Reports Q4 Decline, Announces Dividend
Neuland Laboratories' Q4 results show a 13.68% year-over-year revenue decrease to ₹3.28 billion. Net profit fell 58.86% to ₹278.10 million, with EBITDA margin contracting to 15.55%. Despite the downturn, the company recommended a final dividend of ₹12.00 per equity share, subject to shareholder approval.
Neuland Laboratories
16,049.00
+495.00
(+3.18%)
1 Year Returns:+26.54%
Industry Peers
Sun Pharmaceutical
1,616.60
(+0.43%)
Divis Laboratories
6,026.50
(+0.18%)
Cipla
1,574.60
(+0.88%)
Torrent Pharmaceuticals
3,566.20
(-0.49%)
Dr Reddys Laboratories
1,316.70
(+1.04%)
Mankind Pharma
2,579.60
(-0.75%)
Zydus Life Science
1,044.75
(+0.11%)
Lupin
2,043.40
(+2.79%)
Abbott
30,980.00
(+0.02%)
Alkem Laboratories
5,448.00
(+1.01%)